Methylphenidate augmentation during antidepressant treatment for depression in HIV: a case report

A Primatanti*

Faculty of Medicine and Health Sciences, Universitas Warmadewa
Jalan Terompong 24, Denpasar-Bali, Indonesia

*dr.asih@gmail.com

Abstract. Depression is prevalent among patients with severe or chronic illnesses. Fatigue and apathy are symptoms that are commonly encountered in such conditions. Methylphenidate as a central nervous system stimulant might present additional benefits when administered as an additional therapy for depression. We present a case report of a patient with HIV infection who had received anti-retroviral therapy to slow down the HIV virus progression and antidepressants as indicated by the diagnosis of major depressive disorder. Due to the delayed response to antidepressants, however, methylphenidate was prescribed as an additional therapy. The administration of methylphenidate helped the patient respond better especially in regard to the chronic fatigue experienced. The improvement of Hamilton Depression Rating Scale (HDRS) was also evident. During the administration of methylphenidate, antidepressants and ART were continuously provided.

1. Introduction
Patients affected with certain diseases, chronic infection, brain trauma, and patients who receive palliative care might present with depressive symptoms. Presenting symptoms include declined cognitive function, sleep disorders, fatigue, and apathy. [1-3] Patients with HIV infection are at a significant risk of experiencing depressive symptoms. With an extended course of depression, patients’ adherence to anti-retroviral (ARV) medication might be affected and this would subsequently lead to increased mortality and morbidity. Some antidepressants have been proposed for managing this condition but only 25% up to 35% patients achieved improvement with antidepressant monotherapy. In this case, the administration of additional medications might be necessary to help maintaining and even improving patients’ quality of life [4].

Methylphenidate is a short-acting stimulant that acts in the central nervous system. This medication is the drug of choice for paediatric patients with attention deficit/hyperactivity disorder (ADHD). The mechanism of action involves increasing the availability of monoamine neurotransmitters in the synapse (e.g. norepinephrine, serotonin and dopamine) by blocking their uptake as well as increasing their release. [5] Methylphenidate could be provided as an additional therapy for conditions that might present simultaneously with depression. This addition might accelerate and enhance the effect of antidepressants, even in patients with history of resistance to antidepressants. [6,7] The side effects induced by methylphenidate are relatively negligible hence its improved tolerability, especially in patients with chronic medical conditions [8,9].

2. Case Report
A 30-year-old HIV positive male entrepreneur presented to the clinic with chief complaints of prolonged weakness and diminished excitement. He was diagnosed with HIV infection four years ago, and contracted the infection from an unprotected intercourse. Two months following the diagnosis, he was urged to receive anti-retroviral therapy (ART) due to the low CD4 count of 260 cells/mm³. The
regimen provided consisted of 150 mg lamivudine, 300 mg zidovudine and 200 mg nevirapine twice daily. Current CD4 count was 600 cells/mm³. One month after receiving ART, he recalled feeling depressed and attempting suicide by cutting his wrist. He quickly ‘came back to clear consciousness’, however, and stopped his action immediately. No formal treatments were sought for the depressed mood. Instead, he drank alcoholic drinks and worked harder to get himself busy to escape the feeling of sadness. Patient’s mother was known to suffer from postpartum depression after giving birth to him.

After some significant period of stability, two years ago he started to feel depressed again. He mentioned feeling more and more useless as his business started to deteriorate. He began to experience frequent sadness, easy fatigability, loneliness, and a feeling of demoralisation. He had tried to control the symptoms himself, until he finally decided to present to the clinic two months ago. After a thorough examination, he met the criteria of major depressive disorder based on Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5). Laboratory results for liver function tests and thyroid hormones were within normal limits. He had previously received 10 milligrams of escitalopram for a month but due to a persistent headache after the start of therapy, the medication was replaced with 20 milligrams of fluoxetine and he still receives the medication to date. He also received five sessions of cognitive behavioural therapy (CBT). With these measures, he reported improvements in his symptoms except for the relatively steady course of easy fatigability and apathy.

He presented with Hamilton Depression Rating Scale score of 20, that subsequently improved to 7. Physical and laboratory examinations revealed no abnormal findings. Changes in body weight, blood pressure, and other side effects were not evident.

The patient was then provided with 10 milligrams of methylphenidate per day that was divided into two doses of 5 milligrams each dose. One dose was taken in the morning, and the other one in the afternoon. After one week, the afternoon dose was then increased to 10 mg as he reported feeling sleepy during afternoon. Three weeks after being provided with methylphenidate, his condition improved greatly. His excitement improved, he resumed his previous activities, and began promote his business. His weakness and fatigue also improved. Once an adequate period of stability has been achieved, methylphenidate tapering off is bound to proceed.

3. Discussions
Depression is the most prevalent neuropsychological disorder encountered in patients with HIV infection and this disorder might occur in any phase of the disease. When not properly managed, depression might affect medication adherence and serve as a predictor for adverse clinical outcomes. [3,10,11] The patient in this case presented with several risk factors for depression, including genetics (the positive family history), social problems relating to employment, and current ART use. These factors might combine to result in an even greater risk for the patient to suffer from depression. In addition, some types of ART such as evafirenz has been associated with depressive symptoms, whereas zidovudine and lamivudine have been associated with fatigue and insomnia. [11]

Methylphenidate has demonstrated efficacy in treating depression in diverse patient populations. Its rapid effect and minimal side effects have been proposed as reasons for this efficacy. [12] During a three weeks period of observation, methylphenidate has been reported to accelerate drug response in patients receiving SSRI when compared to placebo. [7] Despite the unclear mechanism for its efficacy, methylphenidate has been hypothesized to bind to dopamine transporter in the presynaptic cell membrane, which subsequently block dopamine reuptake and increase extracellular dopamine level. This leads to increased amount of post-synaptic dopamine, especially in striatum, which results in increased stimulus and motivation. Methylphenidate also inhibits norepinephrine and serotonin reuptake. [1] This medication has demonstrated its efficacy in patients with chronic fatigue syndrome as indicated from significant improvements in Checklist Individual Scale (CIS) and Visual Analog Scale (VAS) scores when compared to placebo [6].

As demonstrated by the case, addition of methylphenidate for the depression therapy in patients with HIV infection has induced improvements in symptoms, and the improvement is especially profound with fatigability. Methylphenidate has also been proved to be effective to improve a declined
cognitive function and reduce daytime sleepiness among patients with brain trauma. [2] This medication is well absorbed in the intestine with peak plasma concentration achieved within 1 to 3 hours and a half-life of 2 hours. [12] In addition to the regained excitement to go back to work, the patient in this case presented no side effects of methylphenidate, which further delineate its well tolerability [13,14,15].

4. Conclusions
Depression is a mood disorder that commonly occurs in patients with HIV infection. This condition should prompt immediate management to reduce the risk of increased mortality and morbidity. For cases of depression that don’t seem to respond adequately to standard therapy, methylphenidate could be offered as an additional therapy to improve the therapeutic effect of antidepressants. Improvements with methylphenidate appeared relatively rapid and it has virtually negligible side effects. Patients have reported improvements in depressive symptoms (including fatigue, day time sleepiness and lost excitement) within three weeks of methylphenidate administration as an addition to antidepressants. The administration of methylphenidate has no effect on the efficacy of ART taken by the patient.

References
[1] Hardy SE 2008 Methylphenidate for the Treatment of Depressive Symptoms, Including Fatigue and Apathy, in Medically Ill Older Adults and Terminally Ill Adults. The American Journal of Geriatric Pharmacotherapy.
[2] Lee H, Kim SW, Kim JM, Shin IS, Yang SJ, Yoon, JS 2005 Comparing Effects of Methylphenidate, Sertraline and Placebo on Neuropsychiatric Sequele in Patients with Traumatic Brain Injury Hum Psychopharmacol Clin Exp 20: 97-104
[3] Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L 2015 Depression in HIV Infected Patients: A Review Curr Psychiatry Rep 17:530
[4] Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russel JM 2002 The Impact of Treatment Resistant Depression on Health Care Utilization and Costs J Clin Psychiatry; 63:963-971
[5] Dell’Osso B, Ketter TA 2013 Use of Adjunctive Stimulants in Adult Bipolar Depression International Journal of Neuropsychopharmacology 16:55–68
[6] Blockmans D, Persoons P, Van Houdenhove B, Bobbaers H 2006 Does Methylphenidate Reduce the Symptoms of Chronic Fatigue Syndrome? The American Journal Medicine 119, 167.e23-167.e30
[7] Lavretsky H, Park S, Siddarth P, Kumar A, Reynolds CF 2006 Methylphenidate-Enhanced Antidepressant Response to Citalopram in the Elderly: A Double-Blind, Placebo-Controlled Pilot Trial. Am J Geriatr Psychiatry 14:181-185
[8] Morton WA, Stockton GG 2000 Methylphenidate Abuse and Psychiatric Side Effect. Primary Care Companion J Clin Psychiatry 2:159-164
[9] Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Manneli P, Ciccone P 2006 A Randomized, Double-blind, Placebo-controlled Trial of Augmentation With an Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression J Clin Psychopharmacol 26:653-656
[10] Antonini A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cingue P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, MarrA CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Vlarcour V, Wojna WE 2007 Updated research nosology for HIV-associated neurocognitive disorders Neurology 69:1789–99
[11] Kaestner F, Anneken K, Mostert C, Reichelt D, Rothermundt M, Evers S, Husstedt IW 2012 Depression Associated With Antiretroviral Drug Therapy in HIV: Case Report and Overview International Journal of STD & AIDS 23:e14-e19
[12] Homsi J, Walsh D, A Kristine, LeGrand S, DavisM 2000 Methylphenidate for depression in
hospice practice: A case series American Journal of Hospice and Palliative Care Volume 17, Number 6

[13] Ahmadi J 2016 Methylphenidate in the Treatment of Methamphetamine Withdrawal Craving: A Novel Outcome Journal of Drug Abuse vol 2 no 1:03

[14] Plutchik L, Snyder S, Drooker M, Chodoff L, Sheiner P 1998 Methylphenidate in Post Liver Transplant Patients The Academy of Psychosomatic Medicine 39: 118-123

[15] Kerr CW, Drake J, Milch RA, Brazeau DA, Skretny JA, Brazeau GA, Donnelly JP Effects of Methylphenidate on Fatigue and Depression: A Randomized, Double-Blind, Placebo-Controlled Trial Journal of Pain and Symptom Management Vol 43. No 1